U.S. Department of Health and Human Services
Workshop on Immune System Engineering for Targeted Tolerance in Type 1 Diabetes (T1D)

Workshop on Immune System Engineering for Targeted Tolerance in Type 1 Diabetes (T1D)

11/1/2017 5:30 PM
11/2/2017 6:30 PM
Yes
No
(800) 228-9290
​​Program Content
Lisa Spain, Ph.D.
NIDDK
T: 301-451-9871
E: spainl@mail.nih.gov

Meeting Logistics

John Hare
The Scientific Consulting Group, Inc.
T: 301-670-4990
E: jhare@scgcorp.com
North Bethesda
 
Bethesda North Marriott Hotel & Conference Center

Event Details

Background

Type 1 diabetes (T1D) results in part from the autoimmune destruction of the insulin-producing pancreatic beta cells. In T1D, the immune system either fails to establish durable self-tolerance in the first place, or inappropriately activates or fails to downregulate itself after infection or injury. The risk of autoimmunity to beta cells may also be higher as a result of the generation of novel antigens (neoantigens, see the companion workshop). Regardless of the precise etiology of the disease, it may be possible to change its course by interfering with autoimmune pathogenesis and re-establishing tolerance.

This workshop will explore research on deactivating immune responses specifically and safely in T1D and other disease contexts. The workshop will also explore the prospects for engineering immune regulation in the context of autoimmune attack through the direct manipulation of regulatory and other cells for applications in cell therapy.

Meeting Objectives

Intervention based on targeting mechanisms of tolerance has the potential for novel therapeutic agents to prevent or treat the disease, including both immunomodulatory materials and cellular therapy. In this workshop, scientists from diverse fields (bioengineering, microbiome research, cancer immunology, etc.) will come together with diabetes experts to discuss how new knowledge, tools and technologies may be applied to reverse autoimmunity.

  1. Develop and apply new knowledge, tools, and technologies that lead to tolerance, not immunization, in autoimmune T1D:
    1. Tolerizing antigen delivery, including nanoparticles that are directed to tolerizing cell types and organ compartments, and other materials that deliver specific antigens in ways that direct the immune response toward active tolerance
    2. Understanding of anti-inflammatory mechanisms that are specific and can be manipulated or targeted
  2. Develop and apply new knowledge, tools, and technologies to engineer immune system cells for use as highly specific therapeutics:
    1. Redirecting effector immune cells to eliminate pathogenic cell types
    2. Redirecting or strengthening immune regulatory cells to dampen the overactive immune system at sites of autoimmune damage.

Registration Deadline

October 15, 2017

This meeting is being held in conjunction with the Autoantigens Discovery and Characterization in Type 1 Diabetes workshop.​​​​​​

Agenda

A complete agenda will be made available once all speakers and timeslots are confirmed.

Dates

11/1/2017 5:30 – 6:30 p.m.

11/2/2017 8:25 a.m. – 5:40 p.m.

Co-Chairs

Q. Tang, University of California, San Francisco

N. Petrovsky, Flinders University

Confirmed Speakers

B. Anderson, Immusant, Cambridge

T. Brusko, University of Florida

D. Graham, Broad Institute

C. Greenbaum, Benaroya Research Institute at Virginia Mason

J. Hubbell, University of Chicago

C.R. Mackay, Gerald Nepom, Benaroya Research Institute at Virginia Mason

M. Peakman, King's College London

M. Roncarolo, Stanford University

M. Sadelain, Memorial Sloan Kettering Cancer Center

D. Scott, Uniformed Services University of the Health Sciences

M. von Herrath, La Jolla Institute for Allergy and Immunology

Confirmed Panelists

A. Bayer, University of Miami

E. James, Benaroya Research Institute at Virginia Mason

A. Tomei, University of Miami


This meeting is being held in conjunction with the Autoantigens Discovery and Characterization in Type 1 Diabetes workshop.​

Directions/Travel

Hotel Accommodations

Bethesda North Marriott Hotel & Conference Center
5701 Marinelli Road
North Bethesda, MD 20852
Phone:  (301) 822-9200 or (800) 228-9290

Website:  www.marriott.com/hotels/travel/wasbn-bethesda-north-marriott-hotel-and-conference-center
(More hotel information can be obtained from this website.)

Reservations

A block of sleeping rooms has been reserved at the Bethesda North Marriott Hotel & Conference Center in Bethesda, MD. The group rate is the prevailing government rate, currently $231 per night, for single occupancy, plus tax (currently 13%). Participants may make reservations by calling the hotel directly or online at https://aws.passkey.com/e/49189239. The room block will be in effect at the group rate until Tuesday, October 3, 2017, only or until full, whichever comes first. Any room reservations received after that date will be accepted on a space- and rate-availability basis. Check-in time is 4:00 p.m., and checkout time is 12:00 p.m. Any reservation cancellations must be made prior to 4:00 p.m. the day before the scheduled arrival date, or charges will apply.

NIH Visitor Information 

Information on visiting the NIH, campus maps, shuttle schedules, driving directions, security, and more can be found on the NIH Visitor Information page.

Driving Directions

Use the following address for your GPS [5701 Marinelli Road, Rockville, MD]

​​

Minutes

Minutes are currently unavailable.

Attendees

Attendees are currently unavailable.

Abstracts

Submission Deadline: TBA

All abstracts must be submitted via email to Ms. LaKia Thomas, thomaslac@mail.nih.gov, with “Tolerance T1D” in the subject line. Abstract submissions should be no longer than 250 words (not including name and affiliation). Attach the abstract as a Microsoft Word document, and make any relevant comments in the text of the email.

Please follow the instructions below to format an abstract. (Note: Submissions will not be edited for spelling or grammar and will be accepted “as is.”)

  1. The abstract title should be typed in bold font, Title Case Letters (i.e., first letter of each main word capitalized).
  2. List the names, degrees, and institutional affiliations of all authors, and underline the name of the presenting author.
  3. Use 1” margins.
  4. The abstract should not exceed one page.
  5. Simple tables or graphs may be included; however, they must fit within the designated abstract space.
  6. Please use a common font, such as Calibri, Times New Roman, or Arial.
  7. Save the abstract file as: primary authors’ last name_first word in the title (e.g., Smith_AutoAntigens).

Location

Line
  • 5701 Marinelli Road
  • MD 20852
Webinar

Contacts

Line ​​Program Content
Lisa Spain, Ph.D.
NIDDK
T: 301-451-9871
E: spainl@mail.nih.gov

Meeting Logistics

John Hare
The Scientific Consulting Group, Inc.
T: 301-670-4990
E: jhare@scgcorp.com